Evelyn Y.T. Wong, MD

Evelyn Y. Wong, MD, is a Consultant Medical Oncologist of Gastrointestinal Cancer at the National Cancer Centre Singapore.

Articles by Evelyn Y.T. Wong, MD

Evelyn Y. Wong, MD, consultant medical oncologist specializing in gastrointestinal cancers, National Cancer Centre Singapore

Cohort Analysis Shows Importance of Early-Onset CRC Awareness and Investigation: With Evelyn Y. Wong, MD

ByEvelyn Y.T. Wong, MD

September 15th 2025

Dr Wong discusses the growing challenge of early-onset colorectal cancer and the insights from a recent cohort analysis conducted in Singapore.

Dr Wong on Next Steps for Validating the Predictive Utility of Molecular Characteristics in CRC

ByEvelyn Y.T. Wong, MD

September 2nd 2025

Evelyn Y.T. Wong, MD, discusses discussed the potential use of molecular characteristics to predict survival outcomes in early-onset CRC.

Rising Early‑Onset Colorectal Cancer Rates in Asia Underscore Global Trend in Incidence and Need for Coordinated Research Efforts

Dr Wong on Survival Outcomes and Molecular Characteristics of Patients with Early-Onset CRC

ByEvelyn Y.T. Wong, MD

August 5th 2025

Evelyn Y.T. Wong, MD, discusses survival outcomes and molecular characteristics of patients with early-onset colorectal cancer from a cohort in Singapore.

Latest Updated Articles

Cohort Analysis Shows Importance of Early-Onset CRC Awareness and Investigation: With Evelyn Y. Wong, MD
Published: September 15th 2025 | Updated:
Dr Wong on Survival Outcomes and Molecular Characteristics of Patients with Early-Onset CRC
Published: August 5th 2025 | Updated:

Evelyn Y.T. Wong, MD

Articles by Evelyn Y.T. Wong, MD

Cohort Analysis Shows Importance of Early-Onset CRC Awareness and Investigation: With Evelyn Y. Wong, MD

Dr Wong on Next Steps for Validating the Predictive Utility of Molecular Characteristics in CRC

Dr Wong on Survival Outcomes and Molecular Characteristics of Patients with Early-Onset CRC

Latest Updated Articles

Trending on OncLive

FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression

FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma

Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer

Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD

Dr Spencer on First-Line Chemo Selection in Metastatic Pancreatic Adenocarcinoma